157 related articles for article (PubMed ID: 26982101)
41. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab.
Ultsch M; Bevers J; Nakamura G; Vandlen R; Kelley RF; Wu LC; Eigenbrot C
J Mol Biol; 2013 Apr; 425(8):1330-9. PubMed ID: 23357170
[TBL] [Abstract][Full Text] [Related]
42. Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart.
Cheetham GM; Hale G; Waldmann H; Bloomer AC
J Mol Biol; 1998 Nov; 284(1):85-99. PubMed ID: 9811544
[TBL] [Abstract][Full Text] [Related]
43. Role of biological agents in immune-mediated inflammatory diseases.
Efthimiou P; Markenson JA
South Med J; 2005 Feb; 98(2):192-204. PubMed ID: 15759950
[TBL] [Abstract][Full Text] [Related]
44. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
Fujimoto M; Serada S; Mihara M; Uchiyama Y; Yoshida H; Koike N; Ohsugi Y; Nishikawa T; Ripley B; Kimura A; Kishimoto T; Naka T
Arthritis Rheum; 2008 Dec; 58(12):3710-9. PubMed ID: 19035481
[TBL] [Abstract][Full Text] [Related]
45. [Monoclonal antibodies in chronic autoimmune inflammatory diseases].
Semerano L; Boissier MC
Med Sci (Paris); 2009 Dec; 25(12):1108-12. PubMed ID: 20035687
[TBL] [Abstract][Full Text] [Related]
46. Substantial energetic improvement with minimal structural perturbation in a high affinity mutant antibody.
Midelfort KS; Hernandez HH; Lippow SM; Tidor B; Drennan CL; Wittrup KD
J Mol Biol; 2004 Oct; 343(3):685-701. PubMed ID: 15465055
[TBL] [Abstract][Full Text] [Related]
47. A Humanized Monoclonal Antibody against Heat Shock Protein 60 Suppresses Murine Arthritis and Colitis and Skews the Cytokine Balance toward an Anti-Inflammatory Response.
Ulmansky R; Landstein D; Moallem E; Loeb V; Levin A; Meyuhas R; Katzavian G; Yair S; Naparstek Y
J Immunol; 2015 Jun; 194(11):5103-9. PubMed ID: 25904550
[TBL] [Abstract][Full Text] [Related]
48. Effect of IL-17A blockade with secukinumab in autoimmune diseases.
Patel DD; Lee DM; Kolbinger F; Antoni C
Ann Rheum Dis; 2013 Apr; 72 Suppl 2():ii116-23. PubMed ID: 23253932
[TBL] [Abstract][Full Text] [Related]
49. A novel domain antibody rationally designed against TNF-alpha using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides.
Qin W; Feng J; Li Y; Lin Z; Shen B
Mol Immunol; 2007 Mar; 44(9):2355-61. PubMed ID: 17125837
[TBL] [Abstract][Full Text] [Related]
50. The use of ustekinumab in autoimmune disease.
Ryan C; Thrash B; Warren RB; Menter A
Expert Opin Biol Ther; 2010 Apr; 10(4):587-604. PubMed ID: 20218921
[TBL] [Abstract][Full Text] [Related]
51. IL-33: a potential therapeutic target in autoimmune diseases.
Wang S; Ding L; Liu SS; Wang C; Leng RX; Chen GM; Fan YG; Pan HF; Ye DQ
J Investig Med; 2012 Dec; 60(8):1151-6. PubMed ID: 23076162
[TBL] [Abstract][Full Text] [Related]
52. Therapeutic potential of interleukin-17 in inflammation and autoimmune diseases.
Yan JW; Wang YJ; Peng WJ; Tao JH; Wan YN; Li BZ; Mei B; Chen B; Yao H; Yang GJ; Li XP; Ye DQ; Wang J
Expert Opin Ther Targets; 2014 Jan; 18(1):29-41. PubMed ID: 24147601
[TBL] [Abstract][Full Text] [Related]
53. [Therapeutic antibody: new opportunity for immunity and inflammatory diseases].
Sun W; Lin H; Hua F; Hu ZW
Yao Xue Xue Bao; 2012 Oct; 47(10):1306-16. PubMed ID: 23289142
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic human monoclonal antibodies in inflammatory diseases.
Kotsovilis S; Andreakos E
Methods Mol Biol; 2014; 1060():37-59. PubMed ID: 24037835
[TBL] [Abstract][Full Text] [Related]
55. 1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.
James LC; Hale G; Waldmann H; Bloomer AC
J Mol Biol; 1999 Jun; 289(2):293-301. PubMed ID: 10366506
[TBL] [Abstract][Full Text] [Related]
56. Molecular modeling of cardiac glycoside binding by the human sequence monoclonal antibody 1B3.
Paula S; Monson N; Ball WJ
Proteins; 2005 Aug; 60(3):382-91. PubMed ID: 15971203
[TBL] [Abstract][Full Text] [Related]
57. Actemra poised to launch IL-6 inhibitors.
Melton L; Coombs A
Nat Biotechnol; 2008 Sep; 26(9):957-9. PubMed ID: 18779787
[No Abstract] [Full Text] [Related]
58. Increasing stability of antibody via antibody engineering: stability engineering on an anti-hVEGF.
Wang S; Liu M; Zeng D; Qiu W; Ma P; Yu Y; Chang H; Sun Z
Proteins; 2014 Oct; 82(10):2620-30. PubMed ID: 24916692
[TBL] [Abstract][Full Text] [Related]
59. Interference of rheumatoid factor activity by aspartame, a dipeptide methyl ester.
Ramsland PA; Movafagh BF; Reichlin M; Edmundson AB
J Mol Recognit; 1999; 12(5):249-57. PubMed ID: 10777254
[TBL] [Abstract][Full Text] [Related]
60. Interference of rheumatoid factor activity by aspartame, a dipeptide methyl ester.
Ramsland PA; Movafagh BF; Reichlin M; Edmundson AB
J Mol Recognit; 1999; 12(4):249-57. PubMed ID: 10440996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
